Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

total health concept sdn bhd - dha oil -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

health spring australia - docosahexaenoic acid (dha)-rich oil derived from microalgae schizochytrium sp. -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

ferngrove pharmaceuticals australia pty ltd - docosahexaenoic acid (dha)-rich oil derived from microalgae schizochytrium sp., quantity: 250 mg - capsule, soft - excipient ingredients: purified water; glycerol; modified food starch - helps maintain/support healthy eye development ; maintain/support healthy eye function ; maintain/support eye health ; helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; maintain/support cardiovascular system health ; maintain/support brain function ; maintain/support brain health ; maintain/support nervous system health ; maintain/support brain/central nervous system development ; maintain/support nervous system function ; helps maintains/support healthy foetal cns/brain development

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

ferngrove pharmaceuticals australia pty ltd - docosahexaenoic acid (dha)-rich oil derived from microalgae schizochytrium sp., quantity: 375 mg (equivalent: docosahexaenoic acid, qty 150 mg) - capsule, soft - excipient ingredients: modified food starch; purified water; glycerol - helps maintain/support healthy eye development ; maintain/support healthy eye function ; maintain/support eye health ; helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; maintain/support cardiovascular system health ; maintain/support brain function ; maintain/support brain health ; maintain/support nervous system health ; maintain/support brain/central nervous system development ; maintain/support nervous system function ; helps maintains/support healthy foetal cns/brain development

Обʼєднані Арабські Емірати - англійська - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

algal oil (contain epa (eicosapentaenoic acid) 90mg & dha (docosahexaenoic acid) 180mg) -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b pure australia pty ltd - docosahexaenoic acid (dha)-rich oil derived from microalgae schizochytrium sp., quantity: 500 mg (equivalent: docosahexaenoic acid, qty 200 mg) - capsule, soft - excipient ingredients: glycerol; purified water; gelatin; soya oil; flavour - maintain/support healthy eye function ; maintain/support general health and wellbeing ; maintain/support cognitive function/mental function ; maintain/support brain function ; maintain/support brain/central nervous system development ; maintain/support nervous system function

Європейський Союз - англійська - EMA (European Medicines Agency)

viatris healthcare limited - tobramycin - cystic fibrosis; respiratory tract infections - antibacterials for systemic use, - tobi podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis. see sections 4.4 and 5.1 regarding data in different age groups.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - tobramycin, quantity: 28 mg - capsule, hard - excipient ingredients: hypromellose; titanium dioxide; calcium chloride dihydrate; carnauba wax; carrageenan; potassium chloride; butan-1-ol; distearoylphosphatidylcholine; isopropyl alcohol; indigo carmine aluminium lake; sulfuric acid; shellac; purified water; propylene glycol - tobi solution and tobi podhaler are indicated for the management of cystic fibrosis patients with p. aeruginosa infections. safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with fev1 less than or equal to 25 % or greater than or equal to 80 % predicted at screening, or patients colonized with burkholderia cepacia. (see clinical trials)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

herbs of gold pty ltd - natural fish oil -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

natural bio pty limited - euphausia superba oil -